(CercleFinance.com) – The European Medicines Agency (EMA) announces that its Committee for Medicinal Products for Human Use (CHMP) has recommended authorizing the marketing of Evusheld, a treatment combining two monoclonal antibodies, for prevention of COVID-19 from 12 years and 40 kilos.
The two antibodies in the treatment are designed to attach to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering cells and then multiplying there.
To reach its conclusion, the CHMP assessed data from a study involving more than 5,000 people.
The data showed that both injections (150 mg of tixagevimab and 150 mg of cilgavimab), reduced the risk of COVID-19 infection by 77%, with a duration of protection of at least six months.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
